Skip Nav Destination
Issues
1 October 2014
-
Cover Image
Cover Image
The cover shows acetylated histone H3 immunohistochemistry staining of skin biopsy at half an hour after the fifth doses of CUDC-101 treatment in the 275-mg/m2 cohort. CUDC-101 induces the accumulation of acetylated histone H3. For details, see the article by Shimizu and colleagues on page 5032 of this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Highlights
Editorial
Policy Statement
CCR Translations
CCR New Strategies
CCR Perspectives in Drug Approval
FDA Approval Summary: Vemurafenib for Treatment of Unresectable or Metastatic Melanoma with the BRAFV600E Mutation
Geoffrey Kim; Amy E. McKee; Yang-Min Ning; Maitreyee Hazarika; Marc Theoret; John R. Johnson; Qiang Casey Xu; Shenghui Tang; Rajeshwari Sridhara; Xiaoping Jiang; Kun He; Donna Roscoe; W. David McGuinn; Whitney S. Helms; Anne Marie Russell; Sarah Pope Miksinski; Jeanne Fourie Zirkelbach; Justin Earp; Qi Liu; Amna Ibrahim; Robert Justice; Richard Pazdur
Molecular Pathways
Cancer Therapy: Clinical
A Recombinant Modified Vaccinia Ankara Vaccine Encoding Epstein–Barr Virus (EBV) Target Antigens: A Phase I Trial in UK Patients with EBV-Positive Cancer
Graham S. Taylor; Hui Jia; Kevin Harrington; Lip Wai Lee; James Turner; Kristin Ladell; David A. Price; Manjit Tanday; Jen Matthews; Claudia Roberts; Ceri Edwards; Lesley McGuigan; Andrew Hartley; Steve Wilson; Edwin P. Hui; Anthony T. C. Chan; Alan B. Rickinson; Neil M. Steven
Phase II Study of Bevacizumab, Temozolomide, and Hypofractionated Stereotactic Radiotherapy for Newly Diagnosed Glioblastoma
Antonio Omuro; Kathryn Beal; Philip Gutin; Sasan Karimi; Denise D. Correa; Thomas J. Kaley; Lisa M. DeAngelis; Timothy A. Chan; Igor T. Gavrilovic; Craig Nolan; Adilia Hormigo; Andrew B. Lassman; Ingo Mellinghoff; Christian Grommes; Anne S. Reiner; Katherine S. Panageas; Raymond E. Baser; Viviane Tabar; Elena Pentsova; Juan Sanchez; Renata Barradas-Panchal; Jianan Zhang; Geraldine Faivre; Cameron W. Brennan; Lauren E. Abrey; Jason T. Huse
Phase I First-in-Human Study of CUDC-101, a Multitargeted Inhibitor of HDACs, EGFR, and HER2 in Patients with Advanced Solid Tumors
Toshio Shimizu; Patricia M. LoRusso; Kyri P. Papadopoulos; Amita Patnaik; Muralidhar Beeram; Lon S. Smith; Drew W. Rasco; Theresa A. Mays; Glenda Chambers; Anna Ma; Jing Wang; Robert Laliberte; Maurizio Voi; Anthony W. Tolcher
Phase II Study of Cetuximab in Combination with Cisplatin and Radiation in Unresectable, Locally Advanced Head and Neck Squamous Cell Carcinoma: Eastern Cooperative Oncology Group Trial E3303
Ann Marie Egloff; Ju-Whei Lee; Corey J. Langer; Harry Quon; Alec Vaezi; Jennifer R. Grandis; Raja R. Seethala; Lin Wang; Dong M. Shin; Athanassios Argiris; Donghua Yang; Ranee Mehra; John Andrew Ridge; Urjeet A. Patel; Barbara A. Burtness; Arlene A. Forastiere
Personalized Medicine and Imaging
Cancer Therapy: Preclinical
Overexpression of Smad7 Blocks Primary Tumor Growth and Lung Metastasis Development in Osteosarcoma
Audrey Lamora; Julie Talbot; Gwenola Bougras; Jérôme Amiaud; Marion Leduc; Julie Chesneau; Julien Taurelle; Verena Stresing; Marie Cécile Le Deley; Marie Françoise Heymann; Dominique Heymann; Françoise Redini; Franck Verrecchia
Biology of Human Tumors
Clinical Implications of Phosphorylated STAT3 Expression in De Novo Diffuse Large B-cell Lymphoma
Chi Young Ok; Jiayu Chen; Zijun Y. Xu-Monette; Alexandar Tzankov; Ganiraju C. Manyam; Ling Li; Carlo Visco; Santiago Montes-Moreno; Karen Dybkær; April Chiu; Attilio Orazi; Youli Zu; Govind Bhagat; Kristy L. Richards; Eric D. Hsi; William W.L. Choi; J. Han van Krieken; Jooryung Huh; Xiaoying Zhao; Maurilio Ponzoni; Andrés J.M. Ferreri; Francesco Bertoni; John P. Farnen; Michael B. Møller; Miguel A. Piris; Jane N. Winter; L. Jeffrey Medeiros; Ken H. Young
Letters to the Editor
Tumor Stromal Phenotypes Define VEGF Sensitivity—Letter
Gert G. Van den Eynden; Nigel C. Bird; Luc Y. Dirix; Rikke L. Eefsen; Zu-Hua Gao; Gunilla Høyer-Hansen; Martin Illemann; Ali W. Majeed; Peter Metrakos; Andrew R. Reynolds; Ben Vainer; Pieter-Jan van Dam; Steven J. Van Laere; Peter B. Vermeulen; Fernando Vidal-Vanaclocha; Pnina Brodt; for the Liver Metastasis Research Network
Correction
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds